Case Report: Rare Myeloid Sarcoma Development Following Renal Transplantation with KRAS and DNMT3A Gene Mutations

Overview

Journal Diagn Pathol

Publisher Biomed Central

Specialty Pathology

Date 2021 Sep 1

PMID 34465355

Authors

Danyang Wu

Xiaoxuan Lu

Xiaojing Yan

Ran Gao

Affiliations

Soon will be listed here.

Abstract

Background: A high incidence of malignant tumors, such as post-transplant lymphoproliferative disorders (PTLD), Kaposi sarcoma, and renal cancer is common in solid organ and bone marrow transplant recipients. However, myeloid sarcoma (MS) after renal transplantation has rarely been reported and the diagnosis is challenging due to its low incidence.

Case Presentation: Here, we report a rare case of a 49-year-old man who developed myeloid sarcoma (MS) in the transplanted kidney two years after renal transplantation. Next-generation sequencing (NGS) showed mutations of KRAS and DNMT3A genes in the MS, and no gene mutations in the bone marrow. He presented a normal karyotype of 46, XY. Following treatment with 6 cycles of systemic chemotherapy, the patient was in satisfactory condition with stable serum creatinine (sCr) levels at the 1-year follow-up. In addition, we performed a detailed review with emphasis on the clinical manifestations, and the diagnostic and therapeutic processes of another 7 patients who developed MS following renal transplantation.

Conclusions: Our report illustrates the clinical utility of comprehensive genomic profiling in benefiting the diagnosis of MS, the selection of therapeutic strategy and the determination of whether MS is donor-derived.

References

AlGhunaim M, Alsuwaida A, Zaidi S, Kfoury H . First case report of acute myeloid sarcoma post renal transplant. Transplant Proc. 2014; 46(7):2411-3. DOI: 10.1016/j.transproceed.2014.02.007. View

Kawamoto K, Miyoshi H, Yoshida N, Takizawa J, Sone H, Ohshima K . Clinicopathological, Cytogenetic, and Prognostic Analysis of 131 Myeloid Sarcoma Patients. Am J Surg Pathol. 2016; 40(11):1473-1483. DOI: 10.1097/PAS.0000000000000727. View

Ying L, Tian L, Xie Y, Wang Q, Che X, Yan J . A case of ureteral myeloid sarcoma post-renal transplantation. BMC Nephrol. 2018; 19(1):46. PMC: 5830329. DOI: 10.1186/s12882-018-0838-0. View

Girsberger S, Wehmeier C, Amico P, Dirnhofer S, Marti E, Halter J . Donor-derived acute myeloid leukemia in a kidney transplant recipient. Blood. 2013; 122(2):298-300. DOI: 10.1182/blood-2013-04-497875. View

Almond L, Charalampakis M, Ford S, Gourevitch D, Desai A . Myeloid Sarcoma: Presentation, Diagnosis, and Treatment. Clin Lymphoma Myeloma Leuk. 2017; 17(5):263-267. DOI: 10.1016/j.clml.2017.02.027. View

Yunus M, Aziz T, Mubarak M . Posttransplant malignancies in renal transplant recipients: 22-years experience from a single center in Pakistan. Asian Pac J Cancer Prev. 2012; 13(2):575-8. DOI: 10.7314/apjcp.2012.13.2.575. View

Palanisamy A, Persad P, Koty P, Douglas L, Stratta R, Rogers J . Donor-derived myeloid sarcoma in two kidney transplant recipients from a single donor. Case Rep Nephrol. 2015; 2015:821346. PMC: 4419238. DOI: 10.1155/2015/821346. View

Wong R, Ketcham M, Irwin T, Akilesh S, Zhang T, Reyes J . Donor-derived acute promyelocytic leukemia presenting as myeloid sarcoma in a transplanted kidney. Leukemia. 2020; 34(10):2776-2779. PMC: 7515823. DOI: 10.1038/s41375-020-0903-0. View

Kashofer K, Gornicec M, Lind K, Caraffini V, Schauer S, Beham-Schmid C . Detection of prognostically relevant mutations and translocations in myeloid sarcoma by next generation sequencing. Leuk Lymphoma. 2017; 59(2):501-504. PMC: 5743000. DOI: 10.1080/10428194.2017.1339879. View

10.

Ward A, Braun B, Shannon K . Targeting oncogenic Ras signaling in hematologic malignancies. Blood. 2012; 120(17):3397-406. PMC: 3482854. DOI: 10.1182/blood-2012-05-378596. View

11.

Shen J, Du X, Diao X, Zhao L, Wang W, Yu Y . Myeloid Sarcoma Presenting With Multiple Skin and Subcutaneous Mass Without Leukemic Manifestations After Renal Transplantation. Transplant Proc. 2015; 47(7):2227-32. DOI: 10.1016/j.transproceed.2015.06.005. View

12.

Quinlan S, Morton L, Pfeiffer R, Anderson L, Landgren O, Warren J . Increased risk for lymphoid and myeloid neoplasms in elderly solid-organ transplant recipients. Cancer Epidemiol Biomarkers Prev. 2010; 19(5):1229-37. PMC: 2866098. DOI: 10.1158/1055-9965.EPI-09-1220. View

13.

Choi M, Jeon Y, Sun C, Yun H, Hong J, Shin D . RTK-RAS pathway mutation is enriched in myeloid sarcoma. Blood Cancer J. 2018; 8(5):43. PMC: 5964090. DOI: 10.1038/s41408-018-0083-6. View

14.

Kauffman H, McBride M, Cherikh W, Spain P, Delmonico F . Transplant tumor registry: donors with central nervous system tumors1. Transplantation. 2002; 73(4):579-82. DOI: 10.1097/00007890-200202270-00017. View

15.

Williams T, Aljitawi O, Moussa R, McHugh S, Dusing R, Abraha J . First case of donor transmitted non-leukemic promyelocytic sarcoma. Leuk Lymphoma. 2012; 53(12):2530-4. DOI: 10.3109/10428194.2012.695360. View

16.

Magdy M, Karim N, Eldessouki I, Gaber O, Rahouma M, Ghareeb M . Myeloid Sarcoma. Oncol Res Treat. 2019; 42(4):224-229. DOI: 10.1159/000497210. View